000 01020 a2200265 4500
005 20250518075438.0
264 0 _c20200826
008 202008s 0 0 eng d
022 _a1437-4331
024 7 _a10.1515/cclm-2019-0973
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFerraro, Simona
245 0 0 _aMore robust analytical evidence should support the selection of human chorionic gonadotropin assays for oncology application.
_h[electronic resource]
260 _bClinical chemistry and laboratory medicine
_c02 2020
300 _ae61-e63 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aBiological Assay
650 0 4 _aBiomarkers, Tumor
650 0 4 _aChorionic Gonadotropin
650 0 4 _aChorionic Gonadotropin, beta Subunit, Human
650 0 4 _aHumans
700 1 _aPanteghini, Mauro
773 0 _tClinical chemistry and laboratory medicine
_gvol. 58
_gno. 3
_gp. e61-e63
856 4 0 _uhttps://doi.org/10.1515/cclm-2019-0973
_zAvailable from publisher's website
999 _c30463422
_d30463422